AnaptysBio, Inc. (ANAB) Cash Flow Statement

The wide divergence between accounting earnings and cash generation suggests that reported net income is a poor proxy for the company's underlying liquidity health. Investors should monitor whether future cash flows can decouple from lumpy milestone events to provide a more consistent funding source for ongoing R&D.

The inability to generate positive free cash flow on a consistent basis implies that the company remains fundamentally dependent on external capital or intermittent licensing windfalls. This trajectory warrants caution, as the current cash burn rate could accelerate if clinical trial costs for the internal pipeline continue to escalate.

These dramatic fluctuations in working capital suggest that the company's cash position is highly susceptible to the administrative and contractual timing of partner payments. Analysts should interpret these swings as evidence of a business model that lacks the operational maturity to smooth out its cash conversion cycle.

The decision to return capital to shareholders while the core business remains in a cash-burning phase may indicate management's confidence in the royalty floor, yet it simultaneously reduces the liquidity buffer available for pipeline setbacks. Investors should scrutinize whether this capital allocation strategy aligns with the long-term objective of achieving commercial-stage independence.